Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, announced today that two additional patents, as well as two patent grant notices, have issued pertaining to important aspects of its cell-free protein synthesis technology. These two patent issuances bring to 11 the number of patents covering Sutro’s OCFS technology, with 57 additional patent applications in prosecution. The patents issued were Nos. 2003259912 (AUS), “Methods of In Vitro Protein Synthesis,” and 2004293798 (AUS), ”Improved Methods of In Vitro Protein Synthesis”. The European Patent Office issued the patent grant notices.

Back to news